LACTOFOLIN® Tablet: The preferred form of folate

Authors

  • GovindShukla Lactonova Nutripharm (P) Ltd, Makers of Lactofolin tablets 81/3, IDA Mallapur, Hyderabad, Telangana, India-500076.
  • AnushaPalkamshetti Lactonova Nutripharm (P) Ltd, Makers of Lactofolin tablets 81/3, IDA Mallapur, Hyderabad, Telangana, India-500076.
  • K.Srinidhi Lactonova Nutripharm (P) Ltd, Makers of Lactofolin tablets 81/3, IDA Mallapur, Hyderabad, Telangana, India-500076.
  • C.J. Sampath Kumar Lactonova Nutripharm (P) Ltd, Makers of Lactofolin tablets 81/3, IDA Mallapur, Hyderabad, Telangana, India-500076.

Keywords:

Lactofolin®Tablets, L-methylfolate, Anaemia, Neural tube defects (NTDs), Cardiovascular diseases (CVD), Alzheimer's disease

Abstract

Lactofolin Tablets (5- MethylTetraHydroFolate (5-MTHF)) contain the body's preferred form of folate, which play a key role in a variety of biochemical reactions that are required for normal cell division and repair. Folate is the generic term comprising all the various chemical folate forms, which are water soluble B-vitamins, and also include synthetic provitamin folic acid.LMF is highly bioavailable source of folic acid. It is the natural, active form of folic acid which is an integral component of prenatal care, homocysteine management, depression treatment, dementia and cardiovascular concerns. LMF is a vitamin essential for reproductive health. The present paper Reviews the Role of Lactofolin tablets developed by R&D cell of Lactonova Nutripharm Pvt Ltd. Hyderabad for prevention & treatment of disorders including Anaemia, neural tube defects (NTDs), cardiovascular diseases (CVD) & Alzheimer's disease.

Downloads

Published

2021-11-12

Issue

Vol. 4 No. 4 (2018): Vol 4, No. 4 (2018) 2018 Volume - 4 Issue-4

Section

Articles

License

Rights and reuse terms depend on the individual article record. Articles accepted on or after 8 September 2026 are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), provided appropriate credit is given, a link to the licence is supplied and changes are indicated. Earlier content remains governed by the rights and licence notice applicable to that article and is not retrospectively relicensed by this policy. Third-party material identified under a different notice is excluded from the journal licence.